Mesenchymal Stromal Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome
Latest Information Update: 16 Sep 2022
At a glance
- Drugs Remestemcel-L (Primary) ; Dexamethasone
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Biomarker; Therapeutic Use
Most Recent Events
- 13 Sep 2022 Results assessing the efficacy and safety of allogeneic mesenchymal cells in mechanically-ventilated patients with moderate or severe COVID-induced respiratory failure, published in the American Journal of Respiratory and Critical Care Medicine.
- 18 Apr 2022 Status changed from active, no longer recruiting to discontinued.
- 18 Jul 2021 According to a Mesoblast media release, ( 90-day survival outcomes) results presented at International Society for Cell & Gene Therapy (ISCT) Scientific Signatures Series on Cell and Gene Therapies in Lung Diseases and Critical Illnesses